<DOC>
	<DOCNO>NCT02152774</DOCNO>
	<brief_summary>To evaluate ocular hypotensive efficacy Rho kinase Inhibitor ( AR-12286 0.5 % 0.7 % ) ophthalmic solution patient diagnose chronic angle-closure glaucoma treat 6 month . Secondary Outcome Secondary objective : 1 . To evaluate early effect Rho kinase Inhibitor ( AR-12286 ) reduce intraocular pressure ( IOP ) . 2 . To evaluate long term effect drug IOP . 3 . To determine AR-12286 used direct therapy CACG , reduce eliminate structural blockage trabecular meshwork lead development elevate IOP .</brief_summary>
	<brief_title>A Study Assess Effect Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5 % 0.7 % Patients With Chronic Angle-closure Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Angle-Closure</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>1 . Patients 50 85 year old ; either sex . 2 . Patients CACG ≥180⁰ PAS 3 . IOP ≥22 mmHg prior initiation treatment one eye two measurement take two hour apart 4 . No previous intraocular surgery except clear cornea phacoemulsification . 5 . Corrected visual acuity eye ≥20/50 eligible eye 6 . Not 6 diopter spherical equivalent study eye 7 . Not 3 diopter cylinder equivalent study eye 8 . Have give write informed consent , prior investigational procedure . 9 . Ability attend 6month duration study 1 . Open angle glaucoma 2 . Closed angle glaucoma &lt; 180⁰ PAS 3 . Intraocular pressure &gt; 35 mmHg 4 . Severe glaucomatous damage 5 . Known hypersensitivity component formulation ( benzalkonium chloride , etc . ) , topical anesthetic . 6 . Previous intraocular surgery except clear cornea phacoemulsification . 7 . Clinically significant ocular disease ( e.g . corneal edema , uveitis , severe keratoconjunctivitis sicca ) might interfere study . 8 . Ocular medication kind within 30 day baseline visit , exception ocular hypotensive medication and/or drops treatment dry eye syndrome ( may use throughout study ) . 9 . Any abnormality prevent reliable applanation tonometry either eye . 10 . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , endocrine cardiovascular disorder ) might interfere study . 11 . Changes systemic medication could substantial effect IOP anticipate study . 12 . Participation investigational study within past 30 day . 13 . Inability perform reliable VF testing . 14 . Unwilling sign consent form approve Institutional Review Board ( IRB ) New York Eye Ear Infirmary . 15 . Selfreported poor compliance treatment . 16 . Reluctance return schedule followup visit . 17 . Patients able understand nature study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>